Canada - TSX-V:TLT - CA88337V1004 - Common Stock
The current stock price of TLT.CA is 0.195 CAD. In the past month the price decreased by -15.22%. In the past year, price increased by 14.71%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
PRN.CA | PROFOUND MEDICAL CORP | N/A | 165.28M | ||
MIR.CA | MEDMIRA INC | N/A | 64.46M | ||
CNVI.CA | CONAVI MEDICAL CORP | N/A | 37.61M | ||
VVTM.CA | VVT MED INC | N/A | 27.99M | ||
PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 26.13M | ||
NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 22.96M | ||
ASG.CA | AURORA SPINE CORP | N/A | 21.24M | ||
MDX.CA | MEDX HEALTH CORP | N/A | 19.62M | ||
VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 17.53M | ||
THRM.CA | THERMA BRIGHT INC | N/A | 2.84M |
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
THERALASE TECHNOLOGIES INC
41 Hollinger Road
TORONTO ONTARIO M4B 3G4 CA
CEO: Shawn Shirazi
Employees: 20
Phone: 14166995273
The current stock price of TLT.CA is 0.195 CAD.
The exchange symbol of THERALASE TECHNOLOGIES INC is TLT and it is listed on the TSX Venture Exchange exchange.
TLT.CA stock is listed on the TSX Venture Exchange exchange.
9 analysts have analysed TLT.CA and the average price target is 0.71 CAD. This implies a price increase of 266.15% is expected in the next year compared to the current price of 0.195. Check the THERALASE TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
THERALASE TECHNOLOGIES INC (TLT.CA) has a market capitalization of 48.32M CAD. This makes TLT.CA a Nano Cap stock.
THERALASE TECHNOLOGIES INC (TLT.CA) currently has 20 employees.
THERALASE TECHNOLOGIES INC (TLT.CA) has a support level at 0.19 and a resistance level at 0.2. Check the full technical report for a detailed analysis of TLT.CA support and resistance levels.
The Revenue of THERALASE TECHNOLOGIES INC (TLT.CA) is expected to grow by 17.72% in the next year. Check the estimates tab for more information on the TLT.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TLT.CA does not pay a dividend.
THERALASE TECHNOLOGIES INC (TLT.CA) will report earnings on 2025-11-25.
THERALASE TECHNOLOGIES INC (TLT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
ChartMill assigns a technical rating of 2 / 10 to TLT.CA. When comparing the yearly performance of all stocks, TLT.CA turns out to be only a medium performer in the overall market: it outperformed 44.98% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TLT.CA. TLT.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TLT.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 27.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -150.75% | ||
ROE | -409.16% | ||
Debt/Equity | 0.15 |
9 analysts have analysed TLT.CA and the average price target is 0.71 CAD. This implies a price increase of 266.15% is expected in the next year compared to the current price of 0.195.
For the next year, analysts expect an EPS growth of -21.18% and a revenue growth 17.72% for TLT.CA